Table 3. Lipinski and Veber rules of selected thioazo compounds (1-6).
| Compound | MW | iLogP | HBD (nOHNH) | HBA (nON) | nrotb | MR | TPSA | Lipinski #violations | Bio availability score |
| Lipinski* | ≤500 | ≤5 | ≤5 | ≤10 | ≤10 | - | - | ||
| Veber** | - | - | - | - | - | - | ≤ 140 | ||
| 1 | 328.82 | 2.65 | 1 | 3 | 4 | 92.64 | 78.41 | 0 | 0.55 |
| 2 | 314.79 | 2.26 | 1 | 3 | 4 | 87.83 | 78.41 | 0 | 0.55 |
| 3 | 404.48 | 3.47 | 1 | 4 | 6 | 116.59 | 93.2 | 0 | 0.55 |
| 4 | 418.51 | 3.84 | 0 | 4 | 6 | 121.49 | 82.34 | 0 | 0.55 |
| 5 | 421.47 | 3.4 | 1 | 5 | 6 | 120.97 | 122.33 | 0 | 0.55 |
| 6 | 720.5 | 6.24 | 2 | 4 | 9 | 181.57 | 124.78 | 2 | 0.17 |
| Doxorubicin | 543.52 | 2.16 | 6 | 12 | 5 | 132.66 | 206.07 | 3 | 0.17 |
| Paclitaxel | 853.91 | 4.51 | 4 | 14 | 15 | 218.96 | 221.29 | 2 | 0.17 |
| Tamoxifen | 371.51 | 4.64 | 0 | 2 | 8 | 119.72 | 12.47 | 1 | 0.55 |